PURPOSE: [(18)F]Mefway is a novel radiotracer specific to the serotonin 5-HT1A receptor class. In preparation for using this tracer in humans, we have performed whole-body PET studies in mice to evaluate the biodistribution and dosimetry of [(18)F]Mefway. METHODS: Six mice (three females and three males) received IV injections of [(18)F]Mefway and were scanned for 2 h in an Inveon-dedicated PET scanner. Each animal also received a high-resolution CT scan using an Inveon CT. The CT images were used to draw volume of interest on the following organs: the brain, large intestine, stomach, heart, kidneys, liver, lungs, pancreas, bone, spleen, testes, thymus, gallbladder, uterus, and urinary bladder. All organ time-activity curves without decay correction were normalized to the injected activity. The area under the normalized curves was then used to compute the residence times in each organ. Data were analyzed using PMOD and Matlab software. The absorbed doses in mouse organs were computed using the RAdiation Dose Assessment Resource animal models for dose assessment. The residence times in mouse organs were converted to human values using scale factors based on differences between organ and body weights. OLINDA/EXM 1.1 software was used to compute the absorbed human doses in multiple organs for both female and male phantoms. RESULTS: The highest mouse residence times were found in the liver, urinary bladder, and kidneys. The largest doses in mice were found in the urinary bladder (critical organ), kidney, and liver for both females and males, indicating primary elimination via urinary system. The projected human effective doses were 1.21E - 02 mSv/MBq for the adult female model and 1.13E - 02 mSv/MBq for the adult male model. The estimated human biodistribution of [(18)F]Mefway was similar to that of [(11)C]WAY 100,635, a 5-HT1A tracer for which dosimetry has been evaluated in humans. CONCLUSIONS: The elimination of radiotracer was primarily via the kidney and urinary bladder with the urinary bladder being the critical organ. Whole-body mouse imaging can be used as a preclinical tool to provide initial estimates of the absorbed doses of [(18)F]Mefway in humans.
PURPOSE: [(18)F]Mefway is a novel radiotracer specific to the serotonin5-HT1A receptor class. In preparation for using this tracer in humans, we have performed whole-body PET studies in mice to evaluate the biodistribution and dosimetry of [(18)F]Mefway. METHODS: Six mice (three females and three males) received IV injections of [(18)F]Mefway and were scanned for 2 h in an Inveon-dedicated PET scanner. Each animal also received a high-resolution CT scan using an Inveon CT. The CT images were used to draw volume of interest on the following organs: the brain, large intestine, stomach, heart, kidneys, liver, lungs, pancreas, bone, spleen, testes, thymus, gallbladder, uterus, and urinary bladder. All organ time-activity curves without decay correction were normalized to the injected activity. The area under the normalized curves was then used to compute the residence times in each organ. Data were analyzed using PMOD and Matlab software. The absorbed doses in mouse organs were computed using the RAdiation Dose Assessment Resource animal models for dose assessment. The residence times in mouse organs were converted to human values using scale factors based on differences between organ and body weights. OLINDA/EXM 1.1 software was used to compute the absorbed human doses in multiple organs for both female and male phantoms. RESULTS: The highest mouse residence times were found in the liver, urinary bladder, and kidneys. The largest doses in mice were found in the urinary bladder (critical organ), kidney, and liver for both females and males, indicating primary elimination via urinary system. The projected human effective doses were 1.21E - 02 mSv/MBq for the adult female model and 1.13E - 02 mSv/MBq for the adult male model. The estimated human biodistribution of [(18)F]Mefway was similar to that of [(11)C]WAY 100,635, a 5-HT1A tracer for which dosimetry has been evaluated in humans. CONCLUSIONS: The elimination of radiotracer was primarily via the kidney and urinary bladder with the urinary bladder being the critical organ. Whole-body mouse imaging can be used as a preclinical tool to provide initial estimates of the absorbed doses of [(18)F]Mefway in humans.
Authors: Ramin V Parsey; Marie-Jose Belanger; Gregory M Sullivan; Norman R Simpson; Michael G Stabin; Ronald Van Heertum; J John Mann Journal: J Nucl Med Date: 2005-04 Impact factor: 10.057
Authors: Eva Assem-Hilger; Rupert Lanzenberger; Markus Savli; Wolfgang Wadsak; Markus Mitterhauser; Leonhard-Key Mien; Elisabeth Stögmann; Christoph Baumgartner; Kurt Kletter; Susanne Asenbaum Journal: Epilepsy Behav Date: 2010-09-17 Impact factor: 2.937
Authors: Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen Journal: Med Res Rev Date: 2011-06-14 Impact factor: 12.944
Authors: Hui Liu; Richard Laforest; Jiwei Gu; Zonghua Luo; Lynne A Jones; Robert J Gropler; Tammie L S Benzinger; Zhude Tu Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Neil Saigal; Alisha K Bajwa; Sara S Faheem; Robert A Coleman; Suresh K Pandey; Cristian C Constantinescu; Vanessa Fong; Jogeshwar Mukherjee Journal: Synapse Date: 2013-04-18 Impact factor: 2.562
Authors: Jogeshwar Mukherjee; Alisha K Bajwa; Dustin W Wooten; Ansel T Hillmer; Min-Liang Pan; Suresh K Pandey; Neil Saigal; Bradley T Christian Journal: J Comp Neurol Date: 2015-11-18 Impact factor: 3.215
Authors: F Bretin; T Mauxion; G Warnock; M A Bahri; L Libert; C Lemaire; A Luxen; M Bardiès; A Seret; A Plenevaux Journal: Mol Imaging Biol Date: 2014-06 Impact factor: 3.488
Authors: Mathias Kranz; Bernhard Sattler; Solveig Tiepolt; Stephan Wilke; Winnie Deuther-Conrad; Cornelius K Donat; Steffen Fischer; Marianne Patt; Andreas Schildan; Jörg Patt; René Smits; Alexander Hoepping; Jörg Steinbach; Osama Sabri; Peter Brust Journal: EJNMMI Phys Date: 2016-10-21
Authors: Xiaoyun Zhou; Philip H Elsinga; Shivashankar Khanapur; Rudi A J O Dierckx; Erik F J de Vries; Johan R de Jong Journal: Mol Imaging Biol Date: 2017-04 Impact factor: 3.488